Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07187479 · ClinicalTrials.gov registry record · NA

Outcomes of Physiologic Insulin Resensitization (PIR) in Patients With Chronic Kidney Disease and Type 2 Diabetes Mellitus

A NA study of Type 2 Diabetes and Kidney Disease, sponsored by Well Cell Global.

Recruiting
Registry status
NA
Development phase
120
Enrollment target
1
Study location

NCT07187479 is a NA study of Type 2 Diabetes and Kidney Disease that is actively recruiting participants, run by Well Cell Global. The registered enrollment target is 120 participants, below the 1,102-participant average among 288 other Type 2 Diabetes trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07187479, a NA study of Type 2 Diabetes and Kidney Disease, is actively recruiting participants, sponsored by Well Cell Global.

RECRUITING
Registry status
NA
Development phase
120 participants
Enrollment target
1
Study location

Study Summary

The purpose of this research is to evaluate outcomes of physiologic insulin re-sensitization (PIR) in patients with Chronic Kidney Disease (CKD) and Type 2 Diabetes Mellitus (T2DM).

Interventions

  • OTHER Physiologic Insulin Resensitization (PIR)

Study Locations (1)

Arizona

  • Arizona Kidney Disease and Hypertension Center - Phoenix

Trial Details

FieldValue
Enrollment Target 120 participants
Start Date 2025-10-14
Est. Completion 2026-06
Phase NA

Sponsor

Well Cell Global

1 total trials

What the Registry Record Tells You About NCT07187479

The ClinicalTrials.gov registry entry for NCT07187479 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,102-participant average among 288 other Type 2 Diabetes trials with a reported enrollment target (89% lower). The listed sponsor is Well Cell Global, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Type 2 Diabetes appearing as the primary indexed condition, and to 1 intervention - of which Physiologic Insulin Resensitization (PIR) is the first listed.

NCT07187479 reports 1 study location spanning 1 distinct geographic area - top geographies include Arizona.

Frequently Asked Questions

What is clinical trial NCT07187479 about?

NCT07187479 is a clinical study titled "Outcomes of Physiologic Insulin Resensitization (PIR) in Patients With Chronic Kidney Disease and Type 2 Diabetes Mellitus". The purpose of this research is to evaluate outcomes of physiologic insulin re-sensitization (PIR) in patients with Chronic Kidney Disease (CKD) and Type 2 Diabetes Mellitus (T2DM).

What is the current status of trial NCT07187479?

This trial is currently recruiting. It is a NA study. The enrollment target is 120 participants. The study started on 2025-10-14. Estimated completion is 2026-06.

What conditions does trial NCT07187479 study?

This clinical trial studies the following conditions: Type 2 Diabetes, Kidney Disease, Chronic Kidney Disease (Stages 4 and 5).

What interventions are being tested in trial NCT07187479?

The interventions under investigation include: Physiologic Insulin Resensitization (PIR) (OTHER).

Who is sponsoring clinical trial NCT07187479?

This trial is sponsored by Well Cell Global, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07187479 being conducted?

This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Type 2 Diabetes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.